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Increasing evidence suggests that early neurodevelopmental
defects in Huntington’s disease (HD) patients could contribute
to the later adult neurodegenerative phenotype. Here, by using
HD-derived induced pluripotent stem cell lines, we report that
early telencephalic induction and late neural identity are affected
in cortical and striatal populations. We show that a large CAG
expansion causes complete failure of the neuro-ectodermal ac-
quisition, while cells carrying shorter CAGs repeats show gross
abnormalities in neural rosette formation as well as disrupted
cytoarchitecture in cortical organoids. Gene-expression analysis
showed that control organoid overlapped with mature human
fetal cortical areas, while HD organoids correlated with the im-
mature ventricular zone/subventricular zone. We also report that
defects in neuroectoderm and rosette formation could be rescued
by molecular and pharmacological approaches leading to a re-
covery of striatal identity. These results show that mutant hun-
tingtin precludes normal neuronal fate acquisition and highlights
a possible connection between mutant huntingtin and abnormal
neural development in HD.
Huntington’s disease | neurodevelopment | striatal differentiation |
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Huntington’s disease (HD) is an inherited neurodegenerativedisease caused by an expansion of CAG repeats in the
huntingtin gene (HTT). While normal huntingtin (HTT) has a
ubiquitous cellular localization and pleiotropic functions in the
adult brain, mutant HTT (muHTT) appears to have a more se-
lective pathogenic effect, as symptoms mostly relate to the loss of
neurons within the striatum (1) and cortex (2). HTT also plays an
essential role during early development in the organization of
embryonic tissues, and complete loss-of-function of HTT leads
to early embryonic death (3, 4). The fact that mutant HTT can,
however, rescue lethality in HTT-KO embryos, indicates that the
extraembryonic function of huntingtin does not depend on the
length of the CAG tract (5), so that muHTT can rescue for loss
of the wild-type form. Thus, different parts of the protein are
involved in different functions during early development and late
in life. Abnormal brain development has also been linked to the
loss of HTT (6) and increasing evidence suggests a neuro-
developmental component in HD (7, 8). However, what remains
poorly understood is whether the increased striatal and cortical
neuronal vulnerability caused by muHTT is due to specific ef-
fects in the adult brain or if it is caused by abnormal develop-
ment that leads to neurodegeneration in late life.
So far, the main evidence suggesting a neurodevelopmental
component in HD is threefold. First, HTT interacts with a
number of developmental factors (9, 10) and is implicated in
several aspects of neural development, such as epiblast forma-
tion (11, 12), neural rosette and neural tube formation (13, 14),
as well as neuronal survival and cortical maturation and migra-
tion (12, 15, 16). Second, there are predictions that the patho-
logical process develops linearly from birth (17) and, accordingly,
measurement of the intracranial volume as a representation of
the maximal brain growth obtained during development has
shown consistent changes in HD subjects before symptoms arise
(18–20). Third, muHTT knockin mice show delayed acquisition
of early striatal cytoarchitecture in the developing brain, and
display high numbers of cells positive for the SOX2 immature
marker (21). Moreover, conditional expression of muHTT from
conception and until postnatal day 21 produces the same pro-
files of neurodegeneration observed in mice expressing muHTT
throughout adult life (21). Furthermore, omics studies on neu-
ronal cultures derived from HD human induced pluripotent stem
cells (HD-hiPSC) documented developmental alterations in
gene expression and highlighted the down-regulation of the key
neurogenic factor NeuroD1 (8, 22).
However, these studies did not address which precise steps of
development are affected by the mutation, or whether reversal of
an early abnormal phenotype has any consequences on more
advanced stages of maturation of HD neurons. To test this hy-
pothesis, we evaluated the ability of human iPSCs to generate
dorsal cortical and ventral striatal telencephalic identities in the
presence of muHTT. We report that muHTT carrying different
CAG repeat expansions leads to impaired down-regulation of
the pluripotency marker OCT4, combined with lower expression
of the neuroectodermal fate determinant PAX6, and defective
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neural rosette formation. Moreover, muHTT led to defects in
cortical and striatal progenitor and neuronal specification,
cytoarchitecture, and terminal neuronal maturation, with the
HD lines showing an overall immature profile compared with
control cultures and human embryonic brain tissue. Importantly,
both zinc finger protein (ZFP) repressor directed against muHTT
and a pharmacological approach by small molecule efficiently
rescued early and late phenotypes in HD lines.
These data show that muHTT affects neuronal differentiation
from early neuroectodermal fate acquisition to late striatal and
cortical identity. Our data highlight a role for muHTT in neu-
rodevelopment that could lead to the pathological phenotypes
seen in HD patients in later life.
Materials and Methods
Human iPSC Cultures. Nonintegrating HD and control (CTR) iPSC lines were
obtained fromMattis et al. (23). Cell lines were generated by reprogramming
using the Amaxa Human Dermal Fibroblast Nucleofector Kit to express
episomal plasmids, as previously reported (23). The lines/clones used in this
study were regularly tested and maintained mycoplasma-free. Cultures
tested in this work are reported in Table S1. Karyotype for each cell line/
clone was regularly monitored every 3 mo during the passages by Q-banding
analyses (ISENET). Cells were maintained in mTeSR1 medium (Voden) and
plated on Matrigel (Becton Dickinson). At 80% of confluence, iPSC colonies
were mechanically isolated and transferred onto new plates.
Striatal Differentiation.HumanHD and CTR iPSC lines were exposed to striatal
differentiation protocol published in Delli Carri et al. (24). All differentiation
experiments performed in this study have been conducted using cells from
passage 20 to passage 50 (Table S1). Briefly, cells were plated at a density of
0.6 × 105 cells/cm−2 on Matrigel-coated dishes in Matrigel with 10 μM ROCK
inhibitor (Y-27632; Sigma). Cultures were expanded for 2 d until 70%
confluent. The starting differentiation medium included DMEM/F12
(Thermo Fisher) supplemented with N2 and B27 (Life Technologies), 10 μM
SB431542 and 500 nM of LDN (provided by Evotec). Medium was replaced
every day. Starting from day in vitro (DIV) 5, 200 ng/mL SHHC-25II (Tocris)
and 100 ng/mL DKK1 (Peprotech) were added and maintained for 3 wk. At
DIV15 the cell population was detached by Accutase (Millipore) and
replated on Matrigel at a density of 2.5 × 104 cells/cm−2. Finally, the cells were
differentiated in terminal differentiation medium by adding 30 ng/mL BDNF
together with N2 and B27.
Cortical Differentiation. Cortical neurons were generated exposing cells into
cortical differentiation using a three-stage protocol that recapitulates cortical
development (25). The in vitro cortical protocol generates cortical progenitor
cells from iPSCs within 15 d of neural induction by neural induction medium
supplemented with 10 μM SB431542 and 500 nM of LDN (provided by Evo-
tec). Next, a 1:1 mixture of N2 and B27 media was used within 3 wk.
Three-Dimensional Cerebral Organoids. To generate 3D cortical organoids,
adapted Lancaster’s protocols were applied. Confluent cells were detached
by Accutase and plated 10 × 103 cells per well of a 96-well plate (Perfecta3D
hanging drop HDP1096; 3D Biomatrix) in DMEM/F12 with 20% KSR (KSR
medium). At DIV3, spheroids were removed and collected in a 15-mL ca-
nonical tube. After being resuspended in KSR medium, spheroids were
placed in dish plate on an orbital shaker at 70 rpm. When the embryoid
bodies were about 500–600 μm in diameter, we changed the KSR medium
with Neural Induction Medium [same as in Lancaster’s protocol (26)]. After
2–7 d the embryoid bodies become brighter on the outside, indicating
neuroectodermal differentiation. Next, aggregates were transferred
into Matrigel droplets. First the dish are placed into the 37 °C incubator
and incubated for about 20 min to allow the Matrigel to polymerize.
When Matrigel is solidified, 6 mL of Neuronal Differentiation Medium
(same as Lancaster’s) is added in the dish. Half of the neuronal differ-
entiation medium was changed three times a week, keeping the dish on
the orbital shaker.
Electrophysiology. Human iPSC-derived neurons were recordered by whole-
cell patch-clamp at DIV30 of differentiation. Whole-cell patch-clamp re-
cordings have been performed at room temperature (23 °C) in voltage- and
current-clamp mode by using patch-pipettes (3–5 MΩ) made from borosili-
cate glass. Acquisition and data analysis were done using Multiclamp 700B
amplifier, digitized with Digidata 1322, and analyzed with PCLAMP (Mo-
lecular Devices) and Origin (Microcal) software. The series resistance com-
pensation was applied to obtain the maximal response time constants.
Current density was calculated by dividing the amplitude of the current peak
by membrane capacitance. Action potential discharges and total ionic cur-
rent have been evoked in bath solution containing: 155 mM NaCl, 1 mM
CaCl2, 1 mM MgCl2, 3 mM KCl, and 10 mM Hepes/NaOH (pH 7.4). The pi-
pettes were filled with a solution composed of: 128 mM KCl, 10 mM NaCl,
11 mM EGTA, and 10 mM Hepes/KOH (pH 7.4). The patch pipette for the
study of the biophysical properties of voltage-gated Na+ currents was filled
with 120 mM CsCl, 10 mM NaCl, 20 mM TEA-Cl, 10 mM EGTA, 2 mM MgCl2,
4 mM Mg-ATP, and 10 mM Hepes/CsOH (pH 7.4). The extracellular solution
contained: 135 mM NaCl, 1 mM CaCl2, 2 mM MgSO4, 10 mM glucose, 5 mM
tetraethylammonium-Cl, and 10 mM Hepes/NaOH (pH 7.4).
Immunocytochemistry. Cell cultures were fixed in 4% (vol/vol) paraformaldehyde
for 15 min at room temperature at different time points analyzed. Subsequently,
cells were blocked in 5% normal goat serum (NGS; Vector), 0.5% Triton
X-100 diluited in PBS at room temperature. Cells were then incubated overnight
at 4 °C with primary antibodies diluted in solution containing 2.5% NGS and
0.25% Triton X-100. Images were acquired with a Leica DMI 6000B mi-
croscope (10× and 20× objectives) and analyzed with LAS-AF imaging
software and then processed using ImageJ, only to adjust contrast for
optimal RGB. Additional images were acquired with confocal microscope
(40× objectives) and then counted using Cell Profiler. The following pri-
mary antibodies were used: OCT4 (mouse, 1:100; Santa Cruz), PAX6 (rabbit,
1:300; Covance), SOX2 (rabbit 1:200; Millipore), PAX6 (mouse, 1:1,000; DHSB),
FLAG (rabbit, 1:500; Sigma), N-cadherin (1:800; Becton Dickinson), PALS1
(rabbit, 1:500; Santa Cruz), FOXG1 (rabbit, 1:500; StemCulture), GSX2
(rabbit, 1:500; Millipore), ASCL1 (mouse, 1:500; Becton Dickinson), ISLT1/2
(mouse, 1:1,000; Hybridoma Bank), NKX2.1/TTF1 (rabbit, 1:200; Abcam),
βIII-tubulin (rabbit, 1:1,000; Promega), MAP2a/B (mouse, 1:500; Becton
Dickinson), CTIP2 (rat, 1:500; Abcam), DARPP32 (rabbit, 1:200; Abcam),
TBR1 (rabbit, 1:1,000; Abcam), TBR2 (rabbit, 1:100; Abcam). Secondary
antibodies conjugated to Alexa fluorophores 488 or 568 (Molecular Probe,
Life Technologies) were used at a 1:1,000 diluition in PBS at room tem-
perature for 1 h. Nuclei were visualized with Hoechst 33258 (5 μg mL−1;
Life Technologies).
Immunohystochemistry. Organoids were fixed in 4% (vol/vol) paraformal-
dehyde overnight at 4 °C. They were washed in PBS and transferred in a 30%
sucrose solution at 4 °C for 48–72 h. Next, organoids were transferred into
Tissue-Tek OCT compound, frozen immediately on dry ice and stored at
−80 °C. Next, 15-μm-thick sections were generated using a cryostat. Cryo-
sections were washed with PBS and blocked 10% NGS, 0.3% Triton
X-100 in PBS at room temperature. Primary antibodies used were diluited
in solution containing 5% NGS and 0.1% Triton X-100: NESTIN (mouse,
1:300; Millipore), Ki67 (rabbit, 1:500; Abcam), BLBP (rabbit, 1:500; Milli-
pore), p-VIMENTIN (mouse, 1:100; Hybridoma Bank), SOX2 (rabbit, 1:200;
Millipore), MAP2a/B (mouse, 1:500; Becton Dickinson), TBR1 (rabbit, 1:1,000;
Abcam), PAX6 (mouse, 1:1,000; DHSB), TBR2 (rabbit, 1:100; Abcam), CTIP2
(rat, 1:500; Abcam). Secondary antibodies conjugated to Alexa fluorophores
488 or 568 (Molecular Probe, Life Technologies) were used 1:500 diluition in
PBS at room temperature mixed with Hoechst 33258 (5 μg mL−1; Life Tech-
nologies) to visualize nuclei.
ZFPs Cloning Strategy. The coding sequence for ZFP-A repressor designed to
repress muHTT was cut from the corresponding pVAX plasmid using EcoRI-
XbaI. Instead, the ZFPΔDBD sequence was obtained by EcoRI-HindIII di-
gestion from the plasmid pAAV-6P-SEWB-ZFPΔDBD (Evotec) and blunted at
the HindIII site. The sequences were then subcloned into the tetracycling-
regulated lentiviral plasmid FUW-tetO-MCS (Addgene #84008). Constructs
were designed as bicistronic vectors carrying a puromycin resistance gene lo-
cated downstream of the 3′ region of the ZFP coding sequence separated by a
“self-cleaving” T2A peptide (SI Materials and Methods), allowing for enrich-
ment of ZFP-expressing cells upon induction with doxycycline and selection
with puromycin. For the cloning of the ZFPs-T2A-puroR sequences into con-
stitutive plasmid under the control of chicken β-actin promoter, both ZFPs-T2A-
puroR were cut from the lentiviral constructs using EcoRI-AfeI and ligated into
the pCAG-Cre (Addgene #26647) recipient plasmid upon excision of Cre by
EcoRI-NotI digestion and 5′ blunting at the NotI site. Additional details are
reported in SI Materials and Methods.
Real-Time qPCR. MRNA was isolated using TRIzol reagent according to the
manufacture’s instruction (Life Technologies). Potential contaminating DNA
was removed by DNA-free kit (Ambion). Template cDNA was prepared by
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reverse transcription of 500 μg RNA using iScript cDNA Synthesis Kit (Bio-
Rad). qPCR was performed using the CFX96 real-Time System (Bio-Rad). All
reactions were performed in 15 μL containing 50 ng cDNA and SsoFast
EVAGreen Supermix (Bio-Rad). Primer pairs used were reported in SI Mate-
rials and Methods.
Western Blot Analysis. Cell cultures were homogenized in RIPA buffer (Tris·HCl
pH8 50 mM, NaCl 150 mM, SDS 0.1%, NP401%, Sodium deoxycholate 0.5%)
supplemented with PMSF 1 mM, DTT 0.5 mM and protease inhibitor mixture
(Sigma). Total protein was quantified using the BCA Kit (Thermo Scientific).
Twenty micrograms of protein was loaded per track onto a 7.5% SDS/PAGE
gels for OCT4 and NANOG detection. Fifty micrograms of protein was loaded
for N-cadherin per track onto a 7.5% SDS/PAGE gel. Fifty micrograms of
protein was loaded for MAP2a/b and DARPP32 per track onto a 6% and 10%
SDS/PAGE gels, respectively. Protein were transferred onto a nitrocellulose
membrane and blocked in TBS-T with 5% nonfat dry milk (Bio-Rad). Nitro-
cellulose membranes were immunoprobed with OCT3/4 (mouse, 1:1,000;
Santa Cruz), OCT4 1–14 aa (rabbit, 1:1,000; Abcam), OCT4 C-end (rabbit,
1:1,000; Abcam); NANOG (rabbit, 1:500; Abcam); MAP2a/B (mouse, 1:500;
Becton Dickinson); DARPP32 (rabbit, 1:200; Abcam), N-CAD (mouse, 1:500;
Becton Dickinson) at 4 °C overnight. Secondary antibody probing and de-
tection was by use of the ECL Kit (Bio-Rad). α-Tubulin (1:10,000, mouse;
Sigma) and GAPDH (1:3,000, mouse; Abcam) were used to normalize. The
acquisitions were performed by Chemidoc MP (Bio-Rad) and densitometric
analysis was performed by Image Lab software.
Microarray Analysis. To perform the microarray analysis, the Illumina
HumanHT-12 v4 Expression BeadChip platform was used to perform dif-
ferential expression analysis on DIV45 and DIV105 of differentiation of iPSC
Q21n1 and Q109n1. A starting amount of 300 ng of high-quality total RNA
was used to generate cDNA and cRNA with the Illumina TotalPrep RNA
Amplification Kit (Illumina). The procedure consisted of RT with an oligo(dT)
primer bearing a T7 promoter using Array-Script. The obtained cDNA be-
came a template for in vitro transcription with T7 RNA polymerase and
biotin UTP, which generated multiple copies of biotinylated cRNA. The
purity and concentration of the cRNA were determined using a NanoDrop
ND-1000 Spectrometer. Quality cRNA was subsequently hybridized using a
direct hybridization array kit (Illumina). Each cRNA sample (1.5 μg) was
hybridized overnight using the HumanHT-12v4 BeadChip array in a
multiple-step procedure; the chips were washed, dried, and scanned on the
BeadArray Reader (Illumina).
Data Processing and Pathway Analysis. Raw microarray data were generated
using BeadStudio v3.0 (Illumina) and background-corrected for P < 0.01.
Absolute expression values were log2-transformed and normalized using
quantile normalization. Principal component analysis (PCA) was performed
using the R package ade4 (27). Transcriptional profiles of CTR and HD
organoids at DIV45 and DIV105 were compared with those of the de-
veloping human fetal brain using a machine-learning algorithm called
CoNTExT that is trained on 1,340 primary tissue samples (28). In particular,
we employed the laminar expression data dissected via laser-capture mi-
crodissection from the fetal human brain. To identify differentially
expressed genes at DIV45, a t test was applied and only genes with P <
0.01 were considered significant. Gene Ontology (GO) analysis of genes with
a higher expression in CTR organoids was performed using the ClueGo
plugin of Cytoscape. The GO “Biological component” was used to query
these genes against the background of all genes expressed in the organoids.
Only GO with a P < 0.01 were considered (κ-score threshold = 0.4). The rest
of the settings were left as defaults. To calculate the semantic similarity
score between GO terms the R package GOSemSim was used (29). The
resulting matrix was then subjected to hierarchical clustering to find the
most represented GO terms. We confirmed the presence of these GO term
clusters with the REVIGO webtool (30). Functional annotation of the genes
differentially expressed in both our organoids at DIV45 and in the study
performed by Ring et al. (22), was performed using Ingenuity Pathway
Analysis (IPA; Ingenuity Systems, https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis/). Microarray data RNA-seq data have
been deposited in the ArrayExpress database at EMBL-EBI (https://www.ebi.
ac.uk/arrayexpress/) under accession no. E-MTAB-5964. More detail is avail-
able in SI Materials and Methods.
Statistical Analysis. One-way ANOVA, Tukey posttest was used for all bi-
ological experiments performed on more HD and CTR lines (*P < 0.05, **P <
0.01, ***P < 0.001).
Student t test was used to compare only two groups (#P < 0.05) (Fig. 6 A
and B and Figs. S4 B, C, L, and M and S5 C and D).
Results
Large CAG Repeats in Huntingtin Gene Lead to Neuroectodermal
Acquisition Defects. Integration-free HD and CTR iPSC lines
were previously generated from fibroblasts of subjects carrying
Q21, Q28, Q33, Q60, Q109, and Q180 (respectively with 21, 28,
33, 60, 109, and 180 CAG repeats) (Table S1) (23). Total HTT
mRNA was similar among all iPSC lines and clones (Fig. S1A).
With the aim of investigating the role of muHTT in the early
phases of neural development, we exposed cells to a stepwise
protocol that mimics human ventral telencephalon development
(24, 31) (Fig. 1B).
We first compared the neurogenic potential of all CTR and
HD-iPSC lines and clones by measuring their transition from
pluripotency to neuroectoderm formation to telencephalic speci-
fication, as judged by total numbers of OCT4+, PAX6+, and
FOXG1+ cells at early stages of differentiation. All iPSC lines were
pluripotent, as attested to by OCT4 and SOX2 staining performed
at DIV0 (Fig. S1C). Following dual SMAD-inhibition, CTR lines
Q21n1, Q28n6, and Q33n1 showed the expected PAX6+ ecto-
dermal acquisition and OCT4 down-regulation at DIV15 (Fig. 1 A
and B and Fig. S1D). In contrast, HD lines Q60n5, Q60n8,
Q109n1, Q109n4, Q109n5, Q180n1, and Q180n3 showed that
OCT4+ cells were still present at the same time point (Fig. 1 A–C
and Fig. S1D). Remarkably, at day 8 there was a clear correlation
(r = 0.97, P = 6.4e-15) between the number of OCT4+ cells and the
number of CAG repeats (Fig. 1D). To further check the validity of
the OCT4 immunocytochemistry data, we performed Western blot
and qPCR analyses on two or three, respectively, control lines and
three HD lines (Q60n5, Q109n5, Q180n1), confirming that HD
lines showed defects in OCT4 down-regulation following differ-
entiation (Fig. S1 E and F). Interestingly, and contrary to this
finding, NANOG was completely down-regulated upon differen-
tiation in all CTR and HD lines (Fig. S1 G and H). Increased
PAX6+ cells and mRNA level were found during neuroectodermal
differentiation in all three CTR and in Q60n5 lines, whereas
Q109n1 and Q180n1 lines showed only slowest or modest increases
during differentiation (Fig. 1 A–C and Fig. S1D). In agreement
with this high expression of OCT4 and lower expression of PAX6,
Q109n5 and Q180n1 lines, but not the lines with fewer CAG re-
peats, showed expression of mesodermal markers like α-smooth
muscle actin (α-SMA) and α-fetoprotein (AFP) at a later stage in
culture (32, 33) (Fig. S1 J–L).
These data indicate that CAG expansion in HTT gene spe-
cifically interferes with the down-regulation of the OCT4 pluri-
potency gene, and with the proper acquisition of a PAX6+
neuroectodermal fate.
Defective Ventral Telencephalic and Striatal Identity Acquisition in
HD-Derived Neural Progenitors. Next, we tested the effect of
muHTT at subsequent stages of the developmental program
(i.e., in the emergence of neural rosettes and in the steps that
precede neuronal specification). We focused on HD lines Q60n5
and Q109n1, because they show loss of pluripotency at day
15 and are therefore expected to progress properly toward dif-
ferentiation (Fig. 1D). Fig. 2A shows that at DIV15 cultures
of Q21n1 CTR were composed of typical N-CADHERIN+
(N-CAD+) large rosettes made of polarized NESTIN+ (NES+)
neuroepithelial stem cells, radially aligned around a central lu-
men, whose mean size is of 216.4 ± 80.7 μm2. In contrast, a
significant reduction in lumen size was found in Q60n5 and
Q109n1 lines (area of lumen size in square micrometers Q60n5:
80.13 ± 15.8, Q109n1: 87.1 ± 31.8) (Fig. 2 A and B).
We then analyzed whether the early defects in neuro-
ectodermal acquisition and rosette formation influence the
ability of HD lines to acquire a ventral telencephalic fate, as
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judged by FOXG1 expression, a transcription factor (TF) re-
quired for the development of the mammalian ventral telencephalon
(31, 34). At DIV30 of differentiation, no differences in FOXG1
expression were found between CTR and HD lines, regardless of
their genotype, indicating that the HD mutation does not in-
terfere with the acquisition of proper telencephalic identity
(Fig. 2 C and D).
We then looked at TF expression patterns to distinguish
progenitor, immature, and mature neuronal populations coex-
isting within the human lateral ganglionic eminence (Fig. 2E). To
begin with, we analyzed GSX2 expression, a key regional marker
that identifies early striatal progenitors (31, 35, 36). Strikingly,
we found that the percentage of GSX2+ cells and GSX2 mRNA
levels were significantly reduced in HD lines compared with
CTR lines (Q60n5: 30.22% ± 15%; Q109n1 27.8% ± 3%, vs.
CTR 55.55 ± 11%) (Fig. 2 C, F, and G).
In vivo studies of human fetal development (31) demon-
strate that the GSX2+ cells from the ventricular zone (VZ)
migrate toward the subventricular zone (SVZ) while acquiring
a new positional identity characterized, first, by a double-positive
GSX2+/ASCL1+ state, followed by a GSX2−/ASCL1+ state,
before entering into the marginal zone (MZ) (Fig. 2E). We
detected a 47% and 53% reduction in GSX2+/ASCL1+ cells
and a 32% and 64.3% reduction in ASCL1+ cells, respectively,
in Q60n5 and in Q109n1 lines compared with CTR (Fig. 2 C,
H, and I), as well as lower ASCL1 expression in the Q109n1
line (Fig. 2J).
In the developing human striatum, the postmitotic progenitors
migrate into the MZ and acquire CTIP2 expression (Fig. 2E)
(31, 37). Interestingly, at DIV30 of differentiation the HD lines
showed a marked reduction in the percentage of CTIP2 immu-
nopositive cells (Fig. 2K). Compared with CTRs, Q60n5 and
Q109n1 lines had a 25 ± 5.3% and 30 ± 2.6% drop in the per-
centage of CTIP2+ cells (Fig. 2L). Western blot and qPCR analysis
confirmed the significant reduction in CTIP2 protein and mRNA
expression in HD lines (Fig. 2 M–O). In addition, immunostaining
and qPCR analysis revealed reduced levels of ISLT1 and NKX2.1,
two TF involved in ventralization and expressed both in the SVZ
and MZ, together with CTIP2 (31) (Fig. S2).
We next evaluated the capacity of the HD cells to complete
neuronal maturation and generate striatal neurons. As expected,
CTR lines were very efficient in their neuronal differentiation
capacity, giving rise to dense clusters of βIII-tubulin+ (TUBB3+)
and MAP2+ neurons. Conversely, a decrease in TUBB3+ and
MAP2+ immunoreactive neurons was found in HD lines (Fig. 3A).
Western blot analysis revealed that the decrease in MAP2a/b
isoform levels in HD lines is inversely correlated to the CAGs
expansion (Fig. 3 B and C). The presence of the 70-KDa MAP2c
in the Q109n1 line, an isoform specifically found early in devel-
opment, further confirmed the incomplete or delayed maturation
of these cells (Fig. 3B). Finally, we analyzed the expression of
markers for terminal striatal differentiation, like CTIP2 and
DARPP32. At DIV50, coexpression of these two markers was
observed both in CTR and, to a minor extent, in HD lines (Fig.
3D). Western blot and qPCR analysis for DARPP32 showed a
clear reduction in protein and mRNA levels confirming a defect
of the HD lines when undergoing terminal maturation into
medium spiny neurons (MSNs) (Fig. 3 D–F and Fig. S3A).
Next, we profiled neurons derived from CTR and HD lines for
their electrophysiological properties by patch-clamp analysis at
DIV30. A total number of 328 CTR cells, 180 Q60n5 cells, and
170 Q109n1 cells were registered for the different electrophysi-
ological parameters. Voltage-gated Na+ inward currents evoked
at different membrane potentials showed that 64% (n = 140) of
CTR neurons, 51% (n = 73) of Q60n5 and 20% (n = 41) of
Q109n1 displayed Na+ current peak larger than 500 pA, an ar-
bitrary threshold defined to select in vitro mature stem cell-
derived neurons (24) (Fig. 3G). In parallel, we found that 58%
of CTRs, 41% of Q60n5, but only 8% of Q109n1 neurons dis-
played single spike or repetitive firing upon stimulation (Fig.
3H). Accordingly, the analysis of the Na+ current revealed that
its density peak measured at −20 mV is higher in CTRs (89 ±
7 pA/pF; n = 78) than in Q60n5 (61 ± 10; n = 27) and in Q109n1
(51 ± 6; n = 17) (Fig. 3I). Interestingly, qPCR analysis for the
levels of sodium channel transcripts SCN1B, SCN2B, SCN3B,
and SCN4B, demonstrated a significant decrease in their ex-
pression in HD compared with CTRs (Fig. S3 B–E).
Overall, our data suggest that HD lines are defective in the
acquisition of a GSX2+, ASCL1+, ISLT1+, NKX2.1+ ventral tel-
encephalic progenitor identity and in striatal fate determination
and terminal maturation.
MuHTT Expression Precludes Cortical Specification and Cell
Compartmentalization. To investigate whether muHTT affects
also human cortical neuronal specification, we differentiated one
control (Q21n1) and one HD line (Q109n1) to cortical pro-
jection neuronal cultures (25). Immunostaining and quantifica-
tion for cortical-specific markers revealed a significant reduction
A B
C D
Fig. 1. Neural induction analysis in HD and CTR
iPSCs following striatal differentiation. (A) Immuno-
cytochemistry for OCT4 and PAX6 at DIV8 and 15 of
differentiation in Q21n1 and three HD lines (Q60n5,
Q109n1, Q180n1). (Scale bar, 100 μm; Inset, 50 μm.)
(B) Counts of OCT4+ (red column) and PAX6+ (green
column) cells by the Automatic Nuclei Counter plug
(ITCN) ImageJ plugin both at DIV8 and 15. (C) Counts
of OCT4+ (red column) cells at DIV 8 and 15 and
PAX6+ (green column) cells at DIV 15 by ITCN in CTR
and HD lines. (One-way ANOVA, OCT4: #P < 0.01 be-
tween HD and CTRs at DIV8, one-way ANOVA;
OCT4 and PAX6: ***P < 0.001 between HD and CTRs
at DIV15, one-way ANOVA; n = 3 biological experi-
ments, data are represented as mean ± SEM.) (D)
Graph of OCT4 and CAG length correlation for all
seven HD lines/clones (Q60n5, Q60n8, Q109n1,
Q109n4, Q109n5, Q180n1, and Q180n3) (r = 0.97, P =
6.4e-15 calculated using Pearson correlation).
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in the percentage of TBR2+ and TBR1+ cells in Q109n1-derived
cortical cultures compared with Q21n1 line (Fig. S4 A and B).
Moreover, qPCR analysis also showed a significant reduction
in PAX6, TBR1, and TBR2 transcript levels in Q109n1 cells
(Fig. S4C).
In addition, we exposed two CTR (Q21n1 and Q28n6) and two
HD (Q60n5 and Q109n1) lines to a 3D differentiation protocol
to obtain human cerebral organoids that more closely resemble
in vivo cortical cytoarchitecture (Fig. S4D) (26, 38). We observed
that following neuroectodermal differentiation, CTR cells pre-
sented a radial NES+ and p-VIM+ neuroepithelium surrounding
a fluid-filled cavity reminiscent of an embryonic ventricle, with
polarized distribution of Ki67
+ cells and αPKC+ staining at
DIV60 (Fig. 4A). Strikingly, these structures were completely
absent in HD-derived corticoids. Moreover, NES and p-VIM
staining showed an altered columnar organization with absence
of Ki67
+ cell polarity (Fig. 4A). Accordingly, SOX2+ progenitor
and MAP2+ neuronal populations clearly localized into two
different population compartments in the CTR lines but failed to
segregate in the HD lines at DIV85 (Fig. 4B and Fig. S4E). In
addition, PAX6, TBR1, and CTIP2 expression and compart-
mentalization were also disrupted in HD samples (Fig. 4B and
Fig. S4E).
Collectively, these results reveal that muHTT severely affects
cortical fate differentiation and proper cell organization in 3D
models in vitro.
HD Cerebral Organoids Show an Immature Transcriptional Blueprint.
To explain in detail the impairment observed both in cortical
specification and in cell organization in HD cultures, we evalu-
ated global transcriptional differences between CTR and HD
organoids at DIV45 (n = 3 for each line) and DIV105 DIV (n =
4 for CTR, n = 5 for HD). PCA showed a clear separation of the
HD and CTR iPSC lines in the first principal component (PC1)
at DIV45 and DIV105 (Fig. S4F). To assess the maturity reached
by the CTR and HD organoids at these two time points, we
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Fig. 2. HD lines show defects in ventral telence-
phalic identity acquisition. (A) Immunocytochemistry
for N-CAD in Q21n1 and in Q60n5 and Q109n1 HD
lines at DIV15 of differentiation. [Scale bar, 100 μm;
Inset (the N-CAD staining for each image), 50 μm.] (B)
Counts of lumen size’s area (μm2) in rosettes from HD
and CTRs lines performed by Cell Profiler. (***P <
0.001, one-way ANOVA; n = 3 biological experi-
ments, data are represented as mean ± SEM.) (C)
Immunocytochemistry for FOXG1, GSX2, and GSX2/
ASCL1 in Q21n1, Q60n5, and Q109n1 after neural
induction (DIV30). [FOXG1, GSX2 scale bar: 100 μm;
Inset (Hoechst staining for each image), 100 μm;
GSX2/ASCL1, 50 μm.] (D) qPCR for FOXG1 in CTRs and
Q60n5 and Q109n1 lines at DIV0, 8, 15, and 30 (A.U.).
(E) Scheme of cells transitioning during development
in the striatal anlage. GSX2+ cells found in the VZ
migrate in the SVZ while acquiring identity of pro-
genitors GSX2+/ASCL1+. Their complete maturation
in striatal neurons is confirmed by colocalization of
CTIP2 and DARPP32. (F) Quantification of GSX2+ cells
by the ITCN ImageJ plugin. (CTRs = 55.55 ± 11.36%;
Q60n5 = 30.22 ± 15.1%; Q109n1 = 27.8 ± 3.52%;
*P < 0.05 one-way ANOVA; n = 3 biological experi-
ments, data are represented as mean ± SEM.) (G)
qPCR GSX2 in CTRs, Q60n5, and Q109n1 lines at DIV0,
8, 15, and 30. (A.U., GSX2, CTRs = 2.69 ± 0.76-fold
increase at DIV30 vs. DIV0 vs. 0.9 ± 0.17 and 1.03 ±
0.28 in Q60n5 and Q109n1 fold-increase, respectively;
*P < 0.05, one-way ANOVA; n = 3 biological experi-
ments, data are represented as mean ± SEM.) (H and I)
Quantification of ASCL1+/GSX2+ (H) and ASCL1+ (I)
cells by the ITCN ImageJ plugin. (ASCL1+/GSX2+:
CTRs = 13.7% ± 2.9; Q60n5 = 7.63 ± 0.85; Q109n1 =
7.23 ± 1.08; **P < 0.01 one-way ANOVA; ASCL1+:
CTRs = 27.67 ± 3.05%; Q60n5 = 19.3 ± 2.52%;
Q109n1 = 9.5 ± 1.80%; *P < 0.05 one-way ANOVA;
n = 3 biological experiments, data are represented as
mean ± SEM.) (J) qPCR for ASCL1 in CTRs and
Q60n5 and Q109n1 lines at DIV0, 8, 15, and 30. (A.U.,
ASCL1 DIV 15: CTRs = 275 ± 32.53-fold induction vs.
186.5 ± 37.47 and 2.93 ± 1.58 in Q60n5 and Q109n1
fold-increase, respectively; DIV30 CTRs = 60.5 ± 4.95
vs. 68.4 ± 4.4 and 17.24 ± 10.98 in Q60n5 and Q109n1
fold-increase, respectively; *P < 0.05 one-way ANOVA; n = 3 biological experiments, data are represented as mean ± SEM; #P < 0.05 one way ANOVA.)
(K) Immunocytochemistry for CTIP2 at DIV30 of differentiation. [Scale bar, 100 μm; Inset (Hoechst staining for each image), 100 μm.] (Lower) High magnification
for CTIP2 staining. (Confocal images, scale bar, 50 μm.) (L) Counts of CTIP2+ postmitotic progenitors at DIV30 of differentiation by ITCN ImageJ plugin. (CTIP2+
cells decreased of 42 ± 5.3% and 45 ± 2.6%, respectively, in Q60 and Q109 lines compared with CTRs, **P < 0.01, one-way ANOVA; n = 3 biological experiments,
data are represented as mean ± SEM.) (M) Western blot for CTIP2 at DIV30 of differentiation. CTIP2 protein level was normalized on GAPDH. (N) Graph
represents densitometric analysis performed onWestern blot results from three biological differentiation experiments. (CTRs = 2.02 ± 0.32; Q60n5 = 0.85 ± 0.29;
Q109n1 = 0.18 ± 0.09, HD vs. CTRs ***P < 0.001 one-way ANOVA; Q60n5 vs. Q109n1 #P < 0.05 one-way ANOVA; n = 3 biological experiments, data are rep-
resented as mean ± SEM.) (O) qPCR for CTIP2 in CTRs and Q60n5 and Q109n1 lines at DIV30. (A.U., CTRs = 31.5 ± 11.4; Q60n5 = 12.6 ± 1.08; Q109n1 = 6.75 ± 3.46;
*P < 0.05 one-way ANOVA; n = 3 biological experiments, data are represented as mean ± SEM.)
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compared their transcriptional profiles to those of the tran-
sitioning in vivo laminae of the developing cortex using the
machine-learning algorithm called CoNTExT (28). We found that
Q21n1 DIV45 and DIV105 samples had the strongest overlap [max-
log10(P value) > 50] with the mature suplate zone (SP)/inner cortical
plate (CPi)/outer cortical plate (CPo) and with the subpial granular
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Fig. 3. Defective striatal terminal differentiation and maturation in HD lines. (A) Immunostaining for TUBB3/MAP2 at DIV30 of differentiation of Q60n5 and Q109n1 and
CTR Q21n1. (Confocal images, scale bar, 50 μm.) (B) Representative Western blot for MAP2a/b at DIV30 with corresponding GAPDH levels. (C) Densitometric analysis on
Western blot analysis normalized with GAPDH. (CTRs = 2.77 ± 0.74; Q60n5 = 1.61 ± 0.27; Q109n1 = 0.19 ± 0.04; *P < 0.05, ***P < 0.001, #P < 0.05 one-way ANOVA; n =
3 biological experiments, data are represented as mean ± SEM.) (D) Double immunostaining for CTIP2 and DARPP32 at DIV 50 of differentiation. Arrows indicate striatal
neurons double positive for CTIP2 (red) and DARPP32 (green). [Scale bar, 100 μm; Insets (crops of the same images), 50 μm.] (E) Representative Western blot for DARPP32 at
DIV50with correspondingGAPDH levels. (F) Densitometric analysis onWestern blot analysis. (CTRs= 1.19± 0.21; Q60n5= 0.85± 0.29; Q109n1= 0.18± 0.09; *P< 0.05 one-way
ANOVA; n = 3 biological experiments, data are represented asmean± SEM.) (G) Families of Na+ current traces evoked by the protocol (Lower traces) from iPSC-derived striatal
neurons differentiated in vitro for 30 d. (H) The graph represents the percentage of cells able to generate 1 spike or firing at DIV30 of differentiation. 62% of CTRs, 53% of
Q60n5, and only 8% of Q109 when activated displayed single spike or repetitive firing. (*P < 0.05 one-way ANOVA; n = 3 biological experiments, data are represented as
mean± SEM.) (I) TheNa+ current density recorded at−20mV from the different iPSC-derived neurons. In the graph, each column represents the average of Na+ current density
in recorded cells. (Q21n1 plus Q33n1 n = 78; Q60 n = 27, Q109 n = 17, *P < 0.05 one-way ANOVA; n = 3 biological experiments, data are represented as mean ± SEM.)
A
B
Fig. 4. HD lines show defects in cortical differenti-
ation and cytoarchitecture. (A) Immunocytochemis-
try for αPKC, NESTIN/Ki67 on organoids derived from
Q21n1 and Q109n1. (Scale bar, 100 μm.) These im-
ages are representative of five organoids stained for
each line generated in two independent experi-
ments. Representative confocal images of organoids
stained with NESTIN, Ki67, and p-VIMENTIN. (Scale
bar, 25 μm.) (B) Organoids derived from Q21n1 and
Q109n1, double-stained for SOX2/MAP2. (Scale bar,
100 μm.) Specific cortical markers PAX6/TBR1 and
CTIP2/TBR1. Arrows indicate the structure mimicking
the embryonic ventricle in Q21n1 organoids. Dotted
ovals show SOX2 and MAP2 organization in Q21n1
and Q109n1. (Scale bar, 50 μm.)
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layer (SG), respectively (Fig. 5A, Left). In contrast, Q109n1 sam-
ples had the strongest overlap [max-log10(P value) > 29] with the
VZ/SVZ at DIV45 and with the SP at DIV105 (Fig. 5A, Right). This
result suggests that HD organoids appear to remain “trapped” in the
VZ/SP transitions, while CTR organoids mature to more mature
entities. In line, immunocytochemistry of the organoids show that
HD lines have a lower expression of TBR1 and CTIP2 that are
present in the CTR line (Fig. 4B and Fig. S4E). This confirms
the differences in maturity reached by the CTR line also at the
protein level.
Subsequently, we proceeded in analyzing the differences in
expression at DIV45 to determine early-stage transcriptional
divergences and identified 1,452 differentially expressed genes
(P < 0.01, t test) between the two groups: 685 genes had a higher
expression in Q21n1 organoids and 767 had a higher expression
in the Q109n1 line (Fig. 5B and Dataset S1). To further un-
derstand the biological relevance of the genes that are down-
regulated in HD and that may explain the phenotype observed,
we carried out a GO analysis using the clueGO plugin of Cyto-
scape (39). We then calculated the semantic similarity scores of all
GO-term pairs (P < 0.01) and found a high enrichment for pos-
itive regulation of neuron projection development and chemical
synaptic transmission (Fig. 5C), suggesting an immature tran-
scriptional signature in HD organoids. We then searched for
genes whose expression could be strictly related to muHTT ef-
fects. To do so, and to avoid noise due to the different background
of the HD-iPSC lines, we compared the genes differentially
expressed at DIV45 with the ones determined in another study
comparing transcriptional differences between HD isogenic lines
at the neural progenitor stage (22). We identified 381 genes dif-
ferentially expressed between CTR and HD lines in common for
both studies (Fig. S4G and Dataset S2) and submitted them to an
IPA. Genes with a higher expression in HD organoids were sig-
nificantly associated (P = 2.17E-07) with the main upstream reg-
ulator TGF-β, as shown by Ring et al. (22), whereas low expressed
genes were significantly (P < 7.18E-04) associated with nervous
system development, especially morphology of the cerebral cortex
(Fig. S4H, Left, network with the highest-scored functional path-
ways; Right, heatmap showing genes enriched for these pathways).
SOX11, GAP43, and CELSR3, all transcripts involved in neural
migration and differentiation, were also down-regulated in HD
cells (Fig. S4 I–K), and in E16.5 cortex from the HD mouse model
R6/2 compared with control littermates (Fig. S4 L–N).
Overall, these data indicate that muHTT affects striatal and
cortical cell specification and further neuronal maturation.
Allele-Specific Down-Regulation of muHTT Rescues Neural Induction
Defects in HD Lines.We reasoned that specific down-regulation of
muHTT at early stages of differentiation might reduce or reverse
its adverse effect on neural induction. To confirm this hypothe-
sis, we used a synthetic ZFP (provided by Sangamo) shown to
efficiently work as selective repressor of muHTT. To this aim, a
doxycycline-inducible ZFP type A (FLAG-tagged) protein was
stably expressed in the Q109n5 line, to obtain time-controlled
expression of the muHTT repressor. In this assay we used
Q109n5 cell lines due to the persistent presence of OCT4+ cells
during neural induction (Fig. 1 A–C). As a control, an inducible
Q109n5 stable cell line expressing a DNA binding-domain mutant
inactive version of the ZFP was also generated (ZFPΔDBD).
ZFP-A and ZFPΔDBD expressing Q109n5 cell lines were
exposed to neural induction and analyzed for OCT4 expression
at DIV5 (Fig. S5 A and B). Robust induction of ZFP-A and
A
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Fig. 5. Transcriptional dynamics in CTR and HD
organoids. (A) Rank-rank hypergeometric overlap
maps comparing the transitions between in vivo
laminae in the developing cortex to differentiation
of CTR (Left) and HD (Right) organoids from
DIV45 and 105. Each box shows the color associated
with the −log10(P value) multiplied by the sign of
either up-regulated (Bottom Left of the box) or
down-regulated genes (Top Right of the box) when
comparing the differentially expressed genes (DEGs)
between each layer of the cortex (e.g., VZ vs. SZ) and
DEGs between DIV45 and DIV105. The stronger the
intensity of red, the stronger the overlap between in
vivo transitions and organoid differentiation. IZ, in-
termediate zone. (B) Heat map diagram showing
the expression levels (z-score) of the differentially
expressed genes from the comparison between CTR
and HD organoids (t test, P < 0.01, n = 3 different
biological replicates in each experimental condition,
for each line). (C) Semantic similarity matrix of down-
regulated genes in HD organoids. The semantic sim-
ilarity scores of all GO-term pairs were grouped by
hierarchical clustering and representative GO terms
are shown on the right and were identified by
REVIGO. (GO terms with P < 0.05 are shown. Bar plots
in red have P < 0.01.)
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ZFPΔDBD expression upon 5 d of doxycycline treatment was
confirmed by qPCR (Fig. S5C). As expected, ZFP-A expression
induced a down-regulation of total HTT mRNA that was not
observed for control ZFPΔDBD (Fig. 6A). Interestingly, ZFP-A
expression as judged by anti-FLAG staining, showed a significant
reversion of the incomplete neuroectodermal transition observed
for this line, with a 55% drop in the percentage of OCT4+ cells
(Fig. 6B and Fig. S5B).
These data show that the defects observed during the
pluripotency-to-neuroectodermal transition are directly de-
pendent on expression of muHTT, and that selective down-
regulation of muHTT effectively restores normal frequency of
OCT4+ cells in vitro.
We then decided to investigate whether the early and con-
tinuous down-regulation of muHTT could have an impact at
later maturation stages, on neural rosette formation. To achieve
a robust and continuous silencing of muHTT, we decided to move
the ZFPs into a constitutive plasmid under the control of the chicken
β-actin promoter. Q21n1 and Q109n1 stable cell lines with consti-
tutive expression of the ZFPs showed ZFP expression and HTT
down-regulation at DIV8 (Fig. 6C and Fig. S5D). Rosette lumen size
was evaluated by immunocytochemistry for PALS1 and N-cadherin
in Q109n1 and control cultures expressing ZFPΔDBD and ZFP-A
(Fig. 6D). Quantification of rosettes stained for PALS1 showed a
significant rescue of 52.5% in lumen size in Q109n1 ZFP-A com-
pared with cells expressing control ZFPΔDBD (Fig. 6E).
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Fig. 6. HTT down-regulation by ZFP rescues defects in neural induction. (A) qPCR for total HTT mRNA in Q109n5 line after doxy treatment (+Dox) and
relative control (−Dox) at DIV5 of differentiation. (A.U., *P < 0.05 Student t test. n = 3 biological experiments, data are represented as mean ± SEM.) (B)
Counts of OCT4+ cells by cell profile in ZFP-A and ZFPΔDBD-infected cells in the absence or presence of Dox. (**P < 0.01 one-way ANOVA; n = 3 biological
experiments, data are represented as mean ± SEM.) (C) qPCR for total HTTmRNA in ZFP-A and ZFPΔDBD constitutive Q109n1 line at DIV15 of differentiation.
(A.U., *P < 0.05 one-way ANOVA; n = 3 biological experiments, data are represented as mean ± SEM.) (D) Immunostaining for PALS1/N-cadherin in ZFP-A and
ZFPΔDBD constitutive Q109n1 lines and ZFPΔDBD Q21n1 line at DIV15 of differentiation. [Scale bar, 50 μm; Insets (crops of the PALS1 of the same images),
50 μm.] (E) Counts of lumen size in rosettes in ZFP-A and ZFPΔDBD constitutive Q109n1 and Q21n1 (μm2). (*P < 0.05, **P < 0.01 one-way ANOVA; n =
3 biological experiments, data are represented as mean ± SEM.) (F) Western blot for N-CAD in Q109n1 cells treated with 10 nM ADAM10 inhibitor GI254023X
with respect to untreated cells and Q21n1 at DIV15 of differentiation. MuHTT leads to increase N-CAD cleavage and affects rosettes formation, a phenotype
that is partially rescued by GI254023X treatment. (G) Densitometric analysis of CTF level in Q109n1 cells in the presence or absence of GI254023X and relative
to Q21n1 control line. (*P < 0.05, **P < 0.01 one-way ANOVA; n = 3 biological experiments, data are represented as mean ± SEM.) (H) Immunostaining for
PALS1/N-CAD in Q109n1 treated with GI254023X relative to untreated control at DIV15 of differentiation. (Scale bar, 50 μm.) (I) Counts of area lumen size in
the presence or absence of GI254023X (μm2) (***P < 0.001 Student t test). (J) qPCR for GSX2, (K) SOX11, and (L) CTIP2 transcripts at DIV30 of differentiation in
Q109n1 treated with GI254023X relative to untreated control. (*P < 0.05, **P < 0.01 one-way ANOVA; n = 3 biological experiments, data are represented as
mean ± SEM.) (M) Confocal images of CTIP2 in Q109n1 without and with GI254023X at DIV30 of differentiation. (Confocal images, scale bar, 50 μm.) (N)
Counts of percentage of CTIP2+ cells with cell profile pipeline in Q109n1 without and with GI254023X. (***P < 0.001, *P < 0.05 one-way ANOVA; n = 3 bi-
ological experiments, data are represented as mean ± SEM.)
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Altogether, these data demonstrate that transcriptional si-
lencing of muHTT can have a significant impact in early de-
velopmental HD phenotypes.
Modulation of muHTT Levels During Early Patterning Rescues Later
Striatal Specification Defects. In parallel with ZFP strategy, we
decided to adopt a pharmacological approach by small molecule
to inhibit muHTT deleterious effect from neural rosette stage
(Fig. 2A) to later stages in culture (DIV30). Our previous studies
showed defects in rosette formation in HTT KO mouse ES cells,
due to hyperactive metalloprotease ADAM10 and increased
N-CAD cleavage, as revealed by an elevated N-CAD C-terminal
fragment (CTF) by Western blot (14). We show here that the
presence of muHTT in the Q109n1 line at DIV15 of differen-
tiation leads to a similar increase in the CTF fragment (Fig. 6 F
and G). The GI254023X compound is a selective inhibitor of
ADAM10 activity that is able to restore neural tube defects and
N-CAD cleavage in httMO-Zebrafish embryos (14). Importantly,
exposure to 10 nM GI254023X from DIV5 to DIV8 of differ-
entiation caused a significant reduction in the level of the CTF
fragment, leading to a significant recovery of 54.2% in lumen size
in Q109n1 cells (Fig. 6 F–I). To understand if the rescue in this
early developmental phenotype influences late maturation of the
HD cells at DIV30, we evaluated mRNA levels of general and
striatal specific progenitor markers, such as SOX11, GSX2, and
CTIP2. qPCR for these markers performed at DIV30 of differ-
entiation showed a 50% increase of SOX11 mRNA and 30%
increase in GSX2 and CTIP2 transcript levels upon GI254023X
treatment (Fig. 6 J–L). Accordingly, the percentage of CTIP2+
cells was partially recovered in GI254023X treated Q109n1,
compared with untreated cells (Fig. 6 M and N), and this is ac-
companied by an overall better neuronal differentiation as
judged by Map2/TUBB3 staining (Fig. S5E).
Taken together, these results demonstrate that muHTT nega-
tively affects striatal and cortical specification, differentiation, and
maturation in vitro. This impairment is evident in both 2D mono-
layer neuronal cultures and 3D organoids showing an abnormal
neuroectodermal transition associated with altered cortico/striatal
specification, together with disrupted cellular organization. Strik-
ingly, defects in 2D neuronal induction and striatal differentiation
are successfully rescued by down-regulation of muHTT or phar-
macological inhibition of one of its effectors, ADAM10, from the
earliest step of the differentiation.
Discussion
HTT protein contributes to several cellular pathways during
embryonic development and adulthood. Wild-type HTT is needed
for normal development and its depletion in mouse causes em-
bryonic lethality at E8.5, with severe abnormalities in neuronal
development (40, 41). Mounting evidence suggests that muHTT
could tamper with neuronal development with repercussions
during adulthood that contribute to the HD pathology (42). How-
ever, there is no information as to how an early developmental
defect may affect neuronal function in adulthood or whether
early therapeutic intervention could have a significant disease
modifying effect.
By using nonintegrating human HD-iPSC lines, we demon-
strated that the pathologic expansion of the CAG tract affects
neural cell positional identity, 3D self-organizing capacity, and
terminal maturation. Problems in reaching a mature transcriptional
profile by HD lines was also shown by the HD iPSC Consortium
that revealed that the omics signatures of HD iPSC lines corre-
spond to an earlier stage of mouse development compared with
controls (8). In our study, HD lines show reduced efficiency in
ventral specification with reduced GSX2, CTIP2, and MAP2 ex-
pression compared with controls. Moreover, HD lines manifest a
delayed exit from pluripotency (Q60 and Q109 lines) that is further
exacerbated in highly expanded CAG repeats (Q180 lines), where
cells remained OCT4+ and committed to mesodermal differentia-
tion even after neural induction. This is not surprising, considering
that overexpression of PAX6 does not induce meso-endodermal
fate while PAX6 knockdown does not inhibit meso-endodermal
differentiation (43).
These data also call for a more detailed study on HTT sub-
cellular localization during differentiation and the use of iPSC
lines to reveal potential aberrant interactions between specific
transcription factors and the mutant protein.
In addition to the striatal component, clear alterations in
cortical fate were detected, with reduction of TBR2 and TBR1
levels in HD progenitors compared with controls. Accordingly,
we reveal that polyQ-expanded HTT has a role in cell-to-cell
interaction and tissue organization during cortical development
because defects in neuronal positioning and cell organization
were found in 3D organoids generated from HD iPSCs. These
results, together with those from Barnat et al. and others
showing that HTT removal in postmitotic projection neurons
leads to defects in neuronal migration in the mouse neocortex,
provide further evidence that HTT loss-of-function mechanisms
associated with the pathological expansion can operate during
neural development (40–42, 44). Our HD organoids also revealed
a transcriptional profile characterized by reduced expression of
genes with key roles in neuronal migration and differentiation.
Among them, SOX11, GAP43, and CELSR3 were down-regulated
also during 2D MSN differentiation, thus suggesting a common
effect of muHTT during cortical and striatal differentiation,
which contribute to explaining the selective vulnerability ob-
served in the striatum and cortex of HD patients. This hypothesis
was further sustained by the down-regulation of these transcripts
in the brain of R6/2 embryos.
Importantly, studies of prodromal HD individuals revealed
brain changes decades before the onset of the disease, including
smaller head circumference (45), caudate and putamen atrophy
(46, 47), and striatal and cortical white matter abnormalities
(48), including cortical thinning (47).
Our results suggest that both the striatal and cortical signatures
are flawed during development, with regards to the response to
differentiation cues and ability to self-organize in complex 3D
structures. We also show that the progression through subsequent
steps of the developmental program is affected in a CAG-dependent
manner, with the highest expansion limiting exit from pluripotency,
Q109 and Q60, causing a delay in neuroectoderm formation, fol-
lowed by the inability (greater in the Q109 line) to undergo full
commitment to striatal specification.
Furthermore, our data attest that the defects in the transition
from pluripotency to neuroectoderm can be reverted by down-
regulating muHTT, and that interventions aimed at restoring
defects in neural rosette formation are able to significantly revert
later ventral specification abnormalities.
One major question that arises from these results is whether these
developmental defects may be relevant to the in vivo pathology.
Smaller intracranial volumes in presymptomatic HD patients have
been observed in one study (44); however, this was not replicated in
the TRACK-HD cohort (49). Whether the iPSCs models used here
correctly mimic what happens in HD still need to be investigated. In
general, iPSCs have been widely used to model genetically encoded
pathologies in vitro. In some cases, these cells have shown re-
markably good recapitulation of disease-specific features. This was
the case for Ebert et al. (50), where SMA patient-derived iPSCs
differentiated to motor neurons showed survival and drug responses
also found in patients. Also, Koch et al. (51) successfully used iPSCs
to study Ataxin-3 aggregation in neurons from patients with
Machado-Joseph disease. However, in some cases, iPSCs revealed
subtle cellular characteristics that were not recapitulated (or not
detected) in the patient. For example, long QT syndrome (LQT2)
hiPSC-derived cardiomyocytes generated from a mutation carrier
with normal QT, showed normal QT interval that was 170% longer
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than that of controls (52). This phenotype was only observed in the
iPS-derived cells, while the patient was asymptomatic. This leads us
to conclude that in vitro cell modeling could in some cases ex-
acerbate disease-related conditions that are masked in vivo by
unknown compensatory mechanisms. Thus, later symptomatic
changes in the HD brain could arise from subtle changes during
neurodevelopment that are in some way “camouflaged” or com-
pensated for, in a more complex in vivo environment. However, if
these small alterations were present, they may change the regular
neuronal homeostasis and in the long run lead to the symptoms
observed in HD. To clear how relevant iPSCs are for HD mod-
eling needs further examination.
In conclusion, these results advocate for the theory of HD as a
pathology with a disguised neurodevelopmental component,
where the polyQ expansion alters the canonical developmental
path of striatal and cortical neurons that are therefore more
unstable and susceptible to muHTT during adulthood. Given the
clinical implication of such findings, conclusive in vivo evidence
in humans remains mandatory.
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